 NEW YORK, Jan. 11, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblasts presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at . An archived webcast of the conference presentation will be available for 90 days on the Companys website at . 